manidipine has been researched along with Cardiovascular Diseases in 4 studies
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Safety and tolerability evaluations were based on adverse events, ECG and laboratory tests, and clinically relevant reports of abnormalities." | 6.73 | Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. ( Alberici, M; Lembo, G; Payeras, AC; Sladek, K, 2007) |
| "Manidipine plus delapril is a fixed-dose combination of a third-generation dihydropyridine calcium antagonist and an angiotensin-converting enzyme inhibitor, which is effective in mild-to-moderately hypertensive patients with an inadequate response to monotherapy." | 6.44 | Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage. ( Coca, A, 2007) |
| " Manidipine, unlike other third-generation dihydropyridine derived drugs, blocks T-type calcium channels present in the efferent glomerular arterioles, reducing intraglomerular pressure and microalbuminuria." | 4.87 | Vascular and metabolic properties of manidipine. ( Buset Ríos, N; Fernández-Andrade Rodríguez, C; Rodríguez Esparragón, F; Rodríguez Pérez, JC, 2011) |
| " Safety and tolerability evaluations were based on adverse events, ECG and laboratory tests, and clinically relevant reports of abnormalities." | 2.73 | Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. ( Alberici, M; Lembo, G; Payeras, AC; Sladek, K, 2007) |
| "Manidipine plus delapril is a fixed-dose combination of a third-generation dihydropyridine calcium antagonist and an angiotensin-converting enzyme inhibitor, which is effective in mild-to-moderately hypertensive patients with an inadequate response to monotherapy." | 2.44 | Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage. ( Coca, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buset Ríos, N | 1 |
| Rodríguez Esparragón, F | 1 |
| Fernández-Andrade Rodríguez, C | 1 |
| Rodríguez Pérez, JC | 1 |
| Richard, S | 1 |
| Coca, A | 1 |
| Payeras, AC | 1 |
| Sladek, K | 1 |
| Lembo, G | 1 |
| Alberici, M | 1 |
3 reviews available for manidipine and Cardiovascular Diseases
| Article | Year |
|---|---|
Vascular and metabolic properties of manidipine.
Topics: Albuminuria; Calcium Channel Blockers; Cardiovascular Diseases; Dihydropyridines; Humans; Insulin Re | 2011 |
Vascular effects of calcium channel antagonists: new evidence.
Topics: Animals; Antihypertensive Agents; Arteries; Calcium; Calcium Channel Blockers; Calcium Channels; Cal | 2005 |
Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage.
Topics: Blood Pressure Determination; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2007 |
1 trial available for manidipine and Cardiovascular Diseases
| Article | Year |
|---|---|
Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular | 2007 |